Enrolling

A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis (ADorable-2)

J2T-MC-KGBJ -

The main purpose of this study is to assess the long-term safety and efficacy of lebrikizumab in participants 6 Months to <18 years of age with moderate-to-severe atopic dermatitis.

Enter your city or zip code to find the nearest site

See if You May Qualify

Answer a few questions to see if you meet key criteria for this study.

Trial Summary

Age Range
6 months - 18 years
Conditions the trial is for
Atopic Dermatitis (Eczema)
What the trial is testing?
Lebrikizumab
Could I receive a Placebo?
Yes
Enrollment Goal
250
Trial Dates
Mar 9, 2023 - Jun 2026
How long will I be in the trial?
This study will last about 68 weeks and may include up to 16 planned visits. If participating in the optional extension as well, the study will last approximately 1 additional year for a total of up to 116 weeks and may include up to 29 scheduled visits.
Trial Phase
III

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Have received treatment from study J2T-MC-KGBI

  • Have completed study treatment from study J2T-MC-KGBI

Participants Must Not:

  • Have developed a serious adverse event from participation in study J2T-MC-KGBI

  • Have developed an adverse event from participation in study J2T-MC-KGBI

Lilly Trial Alerts

Sign up to receive updates about new trials and find out when a clinical trial site near you starts enrolling.

Clinical Trial Resources